Abstract Background The glutamate (Glu) and gamma aminobutyric acid (GABA)
hypotheses of schizophrenia were proposed in the 1980s. However, current findings on …

Schizophrenia is a complex neuropsychiatric disorder with a diverse clinical phenotype that
has a substantial personal and public health burden. To advance the mechanistic …

Elevated brain glutamate has been implicated in non-response to antipsychotic medication
in schizophrenia. Biomarkers that can accurately predict antipsychotic non-response from …

A subgroup of patients with schizophrenia is believed to have aberrant excess of glutamate
in the frontal cortex; this subgroup is thought to show poor response to first-line antipsychotic …

Progressive reduction in glutamatergic transmission has been proposed as an important
component of the illness trajectory of schizophrenia. Despite its popularity, to date, this …

Background Brain metabolite abnormalities measured with magnetic resonance
spectroscopy (MRS) provide insight into pathological processes in schizophrenia. Prior meta …

Background: Research on glutamate (Glu) in schizophrenia has so far been inconclusive.
Based on preclinical studies on Glu lactate interaction, researchers have now focused on …

Studies of cellular and cytokine profiles have contributed to the inflammation hypothesis of
schizophrenia; however, precise markers of inflammatory dysfunction remain elusive. A …

Glutamate and N-acetylaspartate have been investigated in the neuropathology of chronic
schizophrenia, with fewer studies focusing on early phase psychosis. Additionally, there has …

Background Antipsychotic drugs are primarily efficacious in treating positive symptoms by
blocking the dopamine D2 receptor, but they fail to substantially improve negative symptoms …